US5907174016 - ADR
MESOBLAST LTD- SPON ADR
NASDAQ:MESO (4/26/2024, 7:03:12 PM)
After market: 6.32 +0.08 (+1.28%)6.24
+0.09 (+1.46%)
Mesoblast Ltd. is a biopharmaceutical company, which engages in the research, development, and market of mesenchymal lineage adult stem cell technology platform. The company is headquartered in Melbourne, Victoria and currently employs 83 full-time employees. The company went IPO on 2004-12-16. The Company’s Remestemcel-L is mesenchymal lineage stromal cell product platform and is in late-stage development for treatment of systemic inflammatory diseases, including Pediatric steroid refractory acute Graft versus Host Disease (SR-aGVHD), acute respiratory distress syndrome (ARDS) and Biologic refractory inflammatory bowel disease. Its Rexlemestrocel-L is mesenchymal lineage precursor cell product platform and is in late-stage development for treatment of advanced chronic heart failure (CHF) and chronic low back pain (CLBP) due to degenerative disc disease. Two products are commercialized in Japan and Europe by the Company’s licensees, and it has a commercial partnership in Europe and China for certain Phase III assets.
MESOBLAST LTD- SPON ADR
L 38 55 Collins St
Melbourne VICTORIA 3000
P: 61396396036
CEO: Silviu Itescu
Employees: 83
Website: https://www.mesoblast.com/
Aggressive stocks to 10X returns call to investors, with the promise of reaching those heights and beyond by 2025.
Here you can normally see the latest stock twits on MESO, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.
Example Twits: